{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(9)"],"submitter":["Oronsky B"],"pubmed_abstract":["For close to 40 years small-cell lung cancer (SCLC) was adrift, as listless, and as idle as a painted ship on a painted ocean, with nary a breeze to blow in the direction of clinical progress or change. The preferred decades-old first line regimen was etoposide-platinum, to which ≥50% of patients respond, followed by decades-old, tired topotecan in second line for platinum sensitive patients, full stop, because there were no approved therapeutic options (nor generally any compelling experimental ones) in third line or beyond. In 2012 SCLC was designated by the U.S. Congress as a \"recalcitrant\" tumor type and for good reason: because most patients relapse, after the generally favorable response in first line, respond poorly, if at all to subsequent therapies, and rarely survive beyond 1 yea"],"journal":["Journal of Cancer"],"pagination":["2945-2953"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9330463"],"repository":["biostudies-literature"],"pubmed_title":["A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)."],"pmcid":["PMC9330463"],"pubmed_authors":["Lybeck M","Oronsky B","Guo X","Abrouk N","Caroen S","Wang X","Yu Z","Reid T"],"additional_accession":[]},"is_claimable":false,"name":"A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).","description":"For close to 40 years small-cell lung cancer (SCLC) was adrift, as listless, and as idle as a painted ship on a painted ocean, with nary a breeze to blow in the direction of clinical progress or change. The preferred decades-old first line regimen was etoposide-platinum, to which ≥50% of patients respond, followed by decades-old, tired topotecan in second line for platinum sensitive patients, full stop, because there were no approved therapeutic options (nor generally any compelling experimental ones) in third line or beyond. In 2012 SCLC was designated by the U.S. Congress as a \"recalcitrant\" tumor type and for good reason: because most patients relapse, after the generally favorable response in first line, respond poorly, if at all to subsequent therapies, and rarely survive beyond 1 yea","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-05-29T16:11:14.452Z","creation":"2025-04-22T16:40:00.963Z"},"accession":"S-EPMC9330463","cross_references":{"pubmed":["35912017"],"doi":["10.7150/jca.75622"]}}